Prognostic value of cyclin B1 protein expression in colorectal cancer.
We used immunohistochemical analysis to study the expression and prognostic impact of cyclin B1, a key molecule for G2-M phase transition during the cell cycle, in a series of 342 curatively resected colorectal carcinomas. In 269 tumors (78.7%), high expression of cyclin B1 in more than 10% of tumor cells was observed, but there was no association between cyclin B1 expression and histopathologic tumor features. Univariate analysis revealed no impact on disease-free and overall survival. Multivariate analysis revealed pT and pN categories, extramural blood vessel invasion, and low-grade tumor cell differentiation as independent prognostic predictors for overall survival, and pT and pN categories and tumor site for disease-free survival. According to our results, high expression of cyclin B1 is a frequent and early event in colorectal carcinomas. However, cyclin B1 expression is neither a predictor of prognosis in patients with colorectal cancer nor a suitable tool for identifying subgroups of patients at higher risk for disease recurrence.
Department of Histopathology, Leeds Teaching Hospitals NHS Trust, England.
Heike
H
Grabsch
Kristina
K
Lickvers
Olaf
O
Hansen
Shinsuke
S
Takeno
Reinhart
R
Willers
Wolfgang
W
Stock
Helmut E
HE
Gabbert
Wolfram
W
Mueller
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology; D019926:Cyclin B / Q000032:analysis*; D056744:Cyclin B1; D018572:Disease-Free Survival; D005260:Female; D016195:G2 Phase; D006801:Humans; D007150:Immunohistochemistry; D007413:Intestinal Mucosa / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D011379:Prognosis
C534699:CCNB1 protein, human; D019926:Cyclin B; D056744:Cyclin B1